FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gautam Borthakur

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Living Beings

Young Adult

Physiology

Co-author Network

Publications

TOP 3
Lakshmikanth Katragadda; Bing Z Carter; Gautam Borthakur
XIAP antisense therapy with AEG 35156 in acute myeloid leukemia.
Aref Al-Kali; Gautam Borthakur; Carlos E Bueso-Ramos; Jorges Cortes; Zeev Estrov; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Ayalew Tefferi; Guillermo Garcia-Manero
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Michael S Mathisen; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Alfonso Quintás-Cardama
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gautam Borthakur (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lakshmikanth Katragadda; Bing Z Carter; Gautam Borthakur
XIAP antisense therapy with AEG 35156 in acute myeloid leukemia.
Expert opinion on investigational drugs 2013;22(5):663-70.
2013: Aref Al-Kali; Gautam Borthakur; Carlos E Bueso-Ramos; Jorges Cortes; Zeev Estrov; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Ayalew Tefferi; Guillermo Garcia-Manero
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
American journal of hematology 2013;88(5):365-9.
2013: Michael S Mathisen; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Alfonso Quintás-Cardama
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Clinical lymphoma, myeloma & leukemia 2013;13(2):139-43.
2013: Yiming Chen; Gautam Borthakur
Lenalidomide as a novel treatment of acute myeloid leukemia.
Expert opinion on investigational drugs 2013;22(3):389-97.
2013: Maro Ohanian; Alfonso Quintas-Cardama; Gautam Borthakur; Jorge E Cortés; Zeev Estrov; Michael Mathisen; Naveen Pemmaraju
Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2013;13(1):93-6.
2012: Alfonso Quintás-Cardama; Farhad Ravandi; Theresa Liu-Dumlao; Sherry Pierce; Gautam Borthakur; Mark Brandt; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Hagop Kantarjian
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Blood 2012;120(24):4840-5.
2012: Gautam Borthakur; Stefan Faderl; Tapan Kadia; Hagop Kantarjian; Rajyalakshmi Luthra; Keyur P Patel; Sherry Pierce; Wei Qiao; Farhad Ravandi; Jorge E Cortes
Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.
Cancer 2012;118(23):5819-22.
2012: Tapan M Kadia; Hagop Kantarjian; Steven Kornblau; Raja Luthra; Sherry Pierce; Gautam Borthakur; Jorge Cortes; Stefan Faderl; Emil J Freireich; Guillermo Garcia-Manero; Farhad Ravandi
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
Cancer 2012;118(22):5550-9.
2012: Y Boumber; R Castoro; Jorge Cortes; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Jean-Pierre J Issa; Elias Jabbour; J Jorgensen; Andrew Lamb; J Autry; Gautam Borthakur; S Wen; Farhad Ravandi
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Leukemia 2012;26(11):2428-31.
2012: Yiming Chen; Jorge Cortes; Zeev Estrov; Stefan Faderl; Hagop Kantarjian; Farhad Ravandi; Kristy Rey; Gautam Borthakur
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Clinical lymphoma, myeloma & leukemia 2012;12(5):341-4.
2012: Stefan Faderl; Jennie Feliu; Alessandra Ferrajoli; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Jan Burger; Marina Konopleva; Farhad Ravandi; Xuemei Wang; Hagop M Kantarjian
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Cancer 2012;118(18):4471-7.
2012: Wei-Gang Tong; William Wierda; Gautam Borthakur; Carlos Bueso-Ramos; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Jianqin Shan; Guillermo Garcia-Manero
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Cancer 2012;118(18):4462-70.
2012: Alfonso Quintás-Cardama; Gautam Borthakur; Jorge Cortes; Zeev Estrov; Hagop Kantarjian; Srdan Verstovsek
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Leukemia research 2012;36(9):1124-7.
2012: Srdan Verstovsek; Sherry Pierce; Ester Pungolino; Elisa Rumi; Deborah A Thomas; Gautam Borthakur; Domenica Caramazza; Mario Cazzola; Jorge E Cortes; Zeev Estrov; Elias Jabbour; Tapan Kadia; Hagop M Kantarjian; Enrica Morra; Francesco Passamonti
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Blood 2012;120(6):1202-9.
2012: Elias Jabbour; Tapan Kadia; Marina Konopleva; Susan O'Brien; William Plunkett; Farhad Ravandi; Gautam Borthakur; Mark Brandt; Jan Burger; Jorge Cortes; Stefan Faderl; Varsha Gandhi; Guillermo Garcia-Manero; Xuelin Huang; Hagop Kantarjian
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2012;12(4):244-51.
2012: Alireza Eghtedar; Zeev Estrov; Stefan Faderl; Alessandra Ferrajoli; Solly George; Hagop M Kantarjian; Robert C Newton; Carol Bivins; Gautam Borthakur; Jan Burger; Jorge Cortes; Peggy A Scherle; Srdan Verstovsek; Farhad Ravandi
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Blood 2012;119(20):4614-8.
2012: Tapan M Kadia; Hagop M Kantarjian; Charles Koller; Sherry Pierce; Gautam Borthakur; Mark Brandt; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Sergerrne York; Farhad Ravandi
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
British journal of haematology 2012;157(3):312-20.
2012: Hagop Kantarjian; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Mary Beth Rios; Jenny Shan; Moshe Talpaz; Stefan Faderl; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Richard Champlin; Jorge Cortes
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Blood 2012;119(9):1981-7.
2012: Alireza Eghtedar; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Hagop Kantarjian; Sherry Pierce; Farhad Ravandi; Guillermo Garcia-Manero
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
American journal of hematology 2012;87(3):317-8.
2012: Aref Al-Kali; Mohamad Ayoubi; Mark Brandt; Jorge E Cortes; Stefan Faderl; Tapan Kadia; Hagop Kantarjian; Sergej Konoplev; Erpei Lin; Farhad Ravandi; Gautam Borthakur
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients.
Haematologica 2012;97(2):235-40.
2012: Stefan Faderl; Varsha Gandhi; Guillermo Garcia-Manero; Elias Jabbour; Gautam Borthakur; Anna L Byrd; Jorge Cortes; Zeev Estrov; Monica Kwari; Farhad Ravandi; Hagop M Kantarjian
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Cancer 2012;118(3):722-8.
2011: Wendy Stock; Anjali Advani; Martha Arellano; Gautam Borthakur; Lloyd Damon; Daniel J DeAngelo; Dan Douer; Tibor Kovacsovics; Mark Litzow; Michael Rytting; Archie Bleyer
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
Leukemia & lymphoma 2011;52(12):2237-53.
2011: Peter P Ruvolo; Vivian Ruvolo; N Zhang; Y H Qui; Michael Andreeff; Gautam Borthakur; Kevin R Coombes; Marina Konopleva; Steven M Kornblau
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
Leukemia 2011;25(11):1711-7.
2011: Jorge Cortes; Guillermo Garcia-Manero; Elias Jabbour; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Jenny Shan; Srdan Verstovsek; Gautam Borthakur; Elizabeth Burton; Hagop Kantarjian
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Clinical lymphoma, myeloma & leukemia 2011;11(5):421-6.
2011: Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jenny Shan; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Jorge Cortes
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(23):3173-8.
2011: Fabio P S Santos; John Wright; Gautam Borthakur; Stefan Faderl; Alessandra Ferrajoli; Hagop Kantarjian; David McConkey; Susan O'Brien; Jorge Cortes
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Clinical lymphoma, myeloma & leukemia 2011;11(4):355-60.
2011: Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Gautam Borthakur; Farhad Ravandi; Srdan Verstovsek; Jianqin Shan; Jorge Cortes
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Haematologica 2011;96(6):918-21.
2011: Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
Cancer 2011;117(10):2145-55.
2011: Fabio P S Santos; Yesid Alvarado; Hagop Kantarjian; Dushyant Verma; Susan O'Brien; Gloria N Mattiuzzi; Farhad Ravandi; Gautam Borthakur; Jorge Cortes
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Cancer 2011;117(5):982-91.
2011: Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jenny Shan; Guillermo Garcia-Manero; William Wierda; Farhad Ravandi; Gautam Borthakur; Mary Beth Rios; Jorge Cortes
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Blood 2011;117(6):1822-7.
2011: Stefan Faderl; Deborah Ann Thomas; Susan O'Brien; Farhad Ravandi; Guillermo Garcia-Manero; Gautam Borthakur; Alessandra Ferrajoli; Srdan Verstovsek; Mohamed Ayoubi; Michael Rytting; Jennie Feliu; Hagop M Kantarjian
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Clinical lymphoma, myeloma & leukemia 2011;11(1):54-9.
2011: Aref Al-Kali; Hagop Kantarjian; Jianqin Shan; Roland Bassett; Alfonso Quintás-Cardama; Gautam Borthakur; Elias Jabbour; Srdan Verstovsek; Susan O'Brien; Jorge Cortes
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Cancer 2011;117(2):327-35.
2011: Juliana Benito; Ingrid Boehm; Gautam Borthakur; Carlos Bueso-Ramos; Dario Campana; Hernan Carol; Wendy Fang; Craig T Jordan; Hagop Kantarjian; Sergej Konoplev; Richard Lock; Hongbo Lu; Yuexi Shi; Elizabeth Shpall; Barbara Szymanska; Deborah A Thomas; William R Wilson; Patrick A Zweidler-McKay; Michael Andreeff; Marina Konopleva
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
PloS one 2011;6(8):e23108.
2011: Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Haematologica 2011;96(1):62-8.
2011: Bing Z Carter; Duncan H Mak; Stephen J Morris; Gautam Borthakur; Elihu Estey; Anna L Byrd; Marina Konopleva; Hagop Kantarjian; Michael Andreeff
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
Apoptosis : an international journal on programmed cell death 2011;16(1):67-74.
2010: Gloria N Mattiuzzi; Jorge E Cortes; Deborah A Blamble; B Nebiyou Bekele; Lianchun Xiao; Maria Cabanillas; Gautam Borthakur; Susan O'Brien; Hagop Kantarjian
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Cancer 2010;116(24):5659-66.
2010: Effrosyni Apostolidou; Andrew Lamb; Deborah Thomas; Ian Burger; Gautam Borthakur; Srdan Verstovsek
Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Clinical lymphoma, myeloma & leukemia 2010;10(4):281-4.
2010: Nikolai Velev; Jorge Cortes; Richard Champlin; Dan Jones; Gabriela Rondon; Sergio Giralt; Gautam Borthakur; Hagop M Kantarjian; Marcos De Lima
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Cancer 2010;116(15):3631-7.
2010: Wei-Gang Tong; Andrew Lamb; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Gautam Borthakur; Jianqin Shan; Sherry Pierce; Mary Beth Rios; Jorge Cortes
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Cancer 2010;116(13):3152-9.
2010: Dushyant Verma; Andrew Lamb; Jianqin Shan; Susan O'Brien; Zeev Estrov; Guillermo Garcia-Manero; Charles Koller; Gautam Borthakur; Jorge Cortes
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Cancer 2010;116(11):2673-81.
2010: Stefan Faderl; Guillermo Garcia-Manero; Zeev Estrov; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Susan O'Brien; Varsha Gandhi; William Plunkett; Anna Byrd; Monica Kwari; Hagop M Kantarjian
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2755-60.
2010: Ismael J Samudio; Seshagiri Duvvuri; Karen Clise-Dwyer; Julie C Watt; Duncan Mak; Andrew Lamb; Dajun Yang; Vivian Ruvolo; Gautam Borthakur
Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells.
Leukemia & lymphoma 2010;51(5):911-9.
2010: Farshid Dayyani; Anthony P Conley; Sara S Strom; William Stevenson; Jorge E Cortes; Gautam Borthakur; Stefan Faderl; Susan O'Brien; Sherry Pierce; Andrew Lamb; Guillermo Garcia-Manero
Cause of death in patients with lower-risk myelodysplastic syndrome.
Cancer 2010;116(9):2174-9.
2010: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith William Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1856-62.
2010: Dan Jones; Hui Yao; Angela Romans; Caroline Dando; Sherry Pierce; Gautam Borthakur; Amy Hamilton; Carlos Bueso-Ramos; Farhad Ravandi; Guillermo Garcia-Manero; Andrew Lamb
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
Genes, chromosomes & cancer 2010;49(2):182-91.
2010: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Marina Konopleva; Alessandra Ferrajoli; Tapan Kadia; Gautam Borthakur; Denise Stigliano; Jianqin Shan; Andrew Lamb
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):392-7.
2010: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Charles Koller; Gautam Borthakur; Brenda Walker; Weiqiang Zhao; Jianqin Shan; Andrew Lamb
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):398-404.
2010: Jeffrey Bryan; Gautam Borthakur
Role of rituximab in first-line treatment of chronic lymphocytic leukemia.
Therapeutics and clinical risk management 2010;7():1-11.
2010: Gautam Borthakur; Elihu E Estey
Therapy of acute myelogenous leukemia in adults.
Cancer treatment and research 2010;145():257-71.
2010: Gautam Borthakur; Xuelin Huang; Andrew Lamb; Stefan Faderl; Farhad Ravandi; Alessandra Ferrajoli; Ritva Torma; Gail Morris; Donald Berry; Jean-Pierre J Issa
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Leukemia & lymphoma 2010;51(1):73-8.
2010: Ali Al Ameri; Charles Koller; Andrew Lamb; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Sherry Pierce; Gloria N Mattiuzzi
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cancer 2010;116(1):93-7.
2009: Farhad Ravandi; Jean-Pierre J Issa; Guillermo Garcia-Manero; Susan O'Brien; Sherry Pierce; Jianqin Shan; Gautam Borthakur; Srdan Verstovsek; Stefan Faderl; Jorge Cortes; Andrew Lamb
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Cancer 2009;115(24):5746-51.
2009: F P S Santos; Stefan Faderl; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Susan O'Brien; Sherry Pierce; Emil J Freireich; Xuelin Huang; Gautam Borthakur; Carlos E Bueso-Ramos; Marcos De Lima; Michael Keating; Jorge Cortes; Andrew Lamb; Farhad Ravandi
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
Leukemia 2009;23(12):2275-80.
2009: Andrew Lamb; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Stefan Faderl; Carlos E Bueso-Ramos; Lynne V Abruzzo; Sherry Pierce; Jianqin Shan; Jean-Pierre J Issa; Guillermo Garcia-Manero
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Cancer 2009;115(22):5202-9.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Taghi Manshouri; Rajyalakshmi Luthra; Zeev Estrov; Sherry Pierce; Mary Ann Richie; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Srdan Verstovsek
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5418-24.
2009: Dushyant Verma; Hagop M Kantarjian; Dan Jones; Rajyalakshmi Luthra; Gautam Borthakur; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Blood 2009;114(11):2232-5.
2009: Elias Jabbour; Daniel Jones; Hagop M Kantarjian; Susan O'Brien; Constantine Tam; Charles Koller; Jan A Burger; Gautam Borthakur; William G Wierda; Jorge Cortes
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood 2009;114(10):2037-43.
2009: Alfonso Quintás-Cardama; Fabio Pires De Souza Santos; Andrew Lamb; Susan O'Brien; Stefan Faderl; Ahmed Awais; Gautam Borthakur; Jorge Cortes
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Cancer 2009;115(17):3935-43.
2009: Yesid Alvarado; Andrew Lamb; Susan O'Brien; Stefan Faderl; Gautam Borthakur; Jan Burger; Jan A Burger; Guillermo Garcia-Manero; Jianqin Shan; Jorge Cortes
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Cancer 2009;115(16):3709-18.
2009: Gautam Borthakur; Edward Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Andrew Lamb
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer 2009;115(14):3217-21.
2009: Alfonso Quintás-Cardama; Jorge E Cortes; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; David Liu; Eric Bleickardt; Tai-Tsang Chen; Hagop M Kantarjian
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer 2009;115(13):2912-21.
2009: R Garg; Stefan Faderl; Guillermo Garcia-Manero; Jorge Cortes; Charles Koller; X Huang; S York; Sherry Pierce; M Brandt; Miloslav Beran; Gautam Borthakur; Andrew Lamb; Farhad Ravandi
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
Leukemia 2009;23(7):1297-302.
2009: Carmen Fava; Hagop M Kantarjian; Elias Jabbour; Susan O'Brien; Nitin Jain; Mary Beth Rios; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Jianqin Shan; Jorge Cortes
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2008: Gautam Borthakur; Andrew Lamb; Xuemei Wang; William Plunkett; Varsha Gandhi; Stefan Faderl; Guillermo Garcia-Manero; Farhad Ravandi; Sherry Pierce; Elihu H Estey
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: Susan O'Brien; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Jorge Cortes; Gautam Borthakur; Sherry Pierce; Guillermo Garcia-Manero; Hagop M Kantarjian
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Cancer 2008;113(11):3186-91.
2008: Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Xuelin Huang; Srdan Verstovsek; Farhad Ravandi; Zeev Estrov; Gautam Borthakur; Monica Kwari; Hagop M Kantarjian
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Cancer 2008;113(8):2090-6.
2008: Masamitsu Yanada; Gautam Borthakur; Guillermo Garcia-Manero; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Andrew Lamb; Elihu Estey
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
Leukemia research 2008;32(10):1505-9.
2008: Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood 2008;112(5):1638-45.
2008: Constantine S Tam; Andrew Lamb; Guillermo Garcia-Manero; Gautam Borthakur; Susan O'Brien; Farhad Ravandi; Jianqin Shan; Jorge Cortes
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Blood 2008;112(3):516-8.
2008: Gautam Borthakur; Yesid Alvarado; Farhad Ravandi-Kashani; Jorge Cortes; Zeev Estrov; Stefan Faderl; Percy Ivy; Carlos Bueso-Ramos; B Nebiyou Bekele; Francis Giles
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Cancer 2008;113(2):360-6.
2008: Brian D Badgwell; Janice N Cormier; Curtis J Wray; Gautam Borthakur; Wei Qiao; Kenneth V Rolston; Raphael E Pollock
Challenges in surgical management of abdominal pain in the neutropenic cancer patient.
Annals of surgery 2008;248(1):104-9.
2008: Elias Jabbour; Andrew Lamb; Dan Jones; Megan Breeden; Guillermo Garcia-Manero; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Jorge Cortes
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Blood 2008;112(1):53-5.
2008: Gautam Borthakur; Samih El Ahdab; Farhad Ravandi; Stefan Faderl; Alessandra Ferrajoli; Beth Newman; Jean-Pierre J Issa; Andrew Lamb
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Leukemia & lymphoma 2008;49(4):690-5.
2008: Guillermo Garcia-Manero; Jianqin Shan; Stefan Faderl; Jorge Cortes; Farhad Ravandi; Gautam Borthakur; William G Wierda; Sherry Pierce; Elihu Estey; Jinsong Liu; X Huang; Andrew Lamb
A prognostic score for patients with lower risk myelodysplastic syndrome.
Leukemia 2008;22(3):538-43.
2007: Masamitsu Yanada; Guillermo Garcia-Manero; Gautam Borthakur; Farhad Ravandi; Andrew Lamb; Elihu Estey
Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.
Cancer 2007;110(12):2756-60.
2007: Gautam Borthakur; Edward Lin; Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Francis Giles; Mary L Browning; Andrew Lamb; Michael Keating; Susan O'Brien
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Cancer 2007;110(11):2478-83.
2007: Gautam Borthakur; And Elihu E Estey
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
Current oncology reports 2007;9(5):373-7.
2007: Masamitsu Yanada; Xuelin Huang; Guillermo Garcia-Manero; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Stefan Faderl; Jean-Pierre J Issa; Andrew Lamb; Elihu Estey
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
British journal of haematology 2007;138(4):555-7.
2007: Andrew Lamb; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Francis Giles; Jorge Cortes
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Gautam Borthakur; Susan O'Brien; William G Wierda; Deborah A Thomas; Jorge E Cortes; Francis Giles; Hagop M Kantarjian; Susan Lerner; Michael J Keating
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Ahmed Aribi; Gautam Borthakur; Farhad Ravandi; Jianqin Shan; Jan Davisson; Jorge Cortes; Andrew Lamb
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Cancer 2007;109(4):713-7.
2007: Francis Giles; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Sherry Pierce; Maher Albitar; Jorge Cortes; Andrew Lamb
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2006: Gautam Borthakur; Andrew Lamb; George Q Daley; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Mary Sugrue; Jorge Cortes
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2004: Gautam Borthakur; Jorge E Cortes
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
International journal of hematology 2004;79(5):411-9.